Your browser doesn't support javascript.
loading
Prevalence, Evolution, and Risk Factors for Advanced Liver Fibrosis in Adults Undergoing Intestinal Transplantation.
Huard, Geneviève; Fiel, M Isabel; Moon, Jang; Iyer, Kishore; Schiano, Thomas D.
Afiliación
  • Huard G; Department of Medicine, Division of Liver Diseases, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
  • Fiel MI; Department of Pathology, Division of Liver Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Moon J; Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Iyer K; Department of Surgery, Intestinal Transplantation and Rehabilitation Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Schiano TD; Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
JPEN J Parenter Enteral Nutr ; 42(7): 1195-1202, 2018 09.
Article en En | MEDLINE | ID: mdl-29534292
ABSTRACT

INTRODUCTION:

Intestinal failure-associated liver disease (IFALD) occurs commonly in intestinal transplant (ITx) candidates receiving parenteral nutrition (PN). The aim of this study is to establish the prevalence and risk factors for advanced liver fibrosis in adults at the time of ITx.

METHODS:

Retrospective chart review of all ITx was performed in adults between January 2000 and May 2014. Advanced liver fibrosis was defined as stage 3 or stage 4 fibrosis.

RESULTS:

Fifty-three patients met the inclusion criteria. The mean age was 50.6 ± 10.9 years, and the majority were female (60.4%) and Caucasian (67.9%). The mean body mass index was 21.7 ± 3.8 kg/m2 and the median duration of PN was 402 (interquartile range 529) days. Advanced liver fibrosis at the time of ITx was found in 13 patients (24.5%). The multivariate analysis revealed that female gender and white race were significant predictors of advanced liver fibrosis. A total bilirubin >3.0 mg/dL for > a month prior to ITx was associated with an odds ratio of 8.9 for advanced fibrosis at the time of ITx but did not reach statistical significance (P = 0.055).

CONCLUSION:

Close to one-quarter of the ITx recipients had advanced liver fibrosis. In the current era of improved PN management, our data suggests that previously reported risk factors for IFALD, such as extreme short gut syndrome and PN duration, may have a lesser impact on development of liver fibrosis. A prolonged duration of bilirubin elevation may be associated with advanced liver fibrosis in patients with IFALD, but this requires validation in a larger cohort.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Órganos / Nutrición Parenteral / Enfermedades Intestinales / Intestinos / Cirrosis Hepática Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JPEN J Parenter Enteral Nutr Año: 2018 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Órganos / Nutrición Parenteral / Enfermedades Intestinales / Intestinos / Cirrosis Hepática Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JPEN J Parenter Enteral Nutr Año: 2018 Tipo del documento: Article País de afiliación: Canadá
...